OSI-296(OSI-296) - 药物靶点：MST1R x c-Met_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

MST1R x c-Met

作用方式

抑制剂

作用机制

MST1R抑制剂(巨噬细胞刺激蛋白受体抑制剂)、c-Met抑制剂(肝细胞生长因子受体抑制剂)

治疗领域

肿瘤

在研适应症-

非在研适应症

肿瘤

原研机构

OSI Pharmaceuticals, Inc.

在研机构-

非在研机构

OSI Pharmaceuticals, Inc.

权益机构-

最高研发阶段终止临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构/序列

分子式C21H19Cl2FN4O3

InChIKeyLVYXERPKYAQGKM-SNVBAGLBSA-N

CAS号1175296-94-2

关联

100 项与 OSI-296 相关的临床结果

登录后查看更多信息

100 项与 OSI-296 相关的转化医学

登录后查看更多信息

100 项与 OSI-296 相关的专利（医药）

登录后查看更多信息

2

项与 OSI-296 相关的文献（医药）

2017-01-25·Science translational medicine1区 · 医学

RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis

1区 · 医学

Article

作者: McHale, Mark ; Welm, Alana L. ; Fornetti, Jaime ; Waltz, Susan E. ; Randall, R. Lor ; Zhao, Ling ; Andrade, Kelsi ; Anderson, Neysi ; Miller, Scott C.

Inhibition of RON kinase prevents pathogenic bone destruction in mouse models and in a first-in-human clinical study.

2013-08-01·Bioorganic & medicinal chemistry letters4区 · 医学

Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases

4区 · 医学

Article

作者: Wild, Robert ; Epstein, David ; Pachter, Jonathan ; Stolz, Kathryn M. ; Jin, Meizhong ; Turton, Roy W. ; Wang, Ti ; Crew, Linda ; Gokhale, Prafulla ; Steinig, Arno G. ; Wang, Jing ; Landfair, Darla ; Mantis, Christine ; Ferraro, Caterina ; Li, An-Hu ; Workman, Jen ; Schulz, Ryan ; Dong, Hanqing ; Cooke, Andy ; Kahler, Jennifer ; Tavares-Greco, Paula A. ; Chen, Xin ; Kadalbajoo, Mridula ; Albertella, Mark R. ; Peng, Yue ; Kan, Julie ; Bittner, Mark ; Mulvihill, Mark J. ; Franklin, Maryland ; Kleinberg, Andrew

A series of novel 6-aminofuro[3,2-c]pyridines as kinase inhibitors is described, most notably, OSI-296 (6). We discuss our exploration of structure-activity relationships and optimization leading to OSI-296 and disclose its pharmacological activity against cMET and RON in cellular assays. OSI-296 is a potent and selective inhibitor of cMET and RON kinases that shows in vivo efficacy in tumor xenografts models upon oral dosing and is well tolerated.

100 项与 OSI-296 相关的药物交易

登录后查看更多信息